News Disease Modifying Drugs Seen to Help Protect MS Patients with Benign Status from Greater Disability Disease Modifying Drugs Seen to Help Protect MS Patients with Benign Status from Greater Disability by Inês Martins, PhD | July 22, 2016 Share this article: Share article via email Copy article link Women with multiple sclerosis (MS) and people diagnosed with the disease at a younger age are more likely to have a benign course of MS, remaining fully functional for decades after disease onset, according to researchers at the School of Medicine and Biomedical Sciences in New York. Disease modifying drugs were also found to help maintain this benign state. The results were published in the journal BMC Neurology, in the study, “Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).” MS is known for following a highly heterogeneous course. Some patients have what is called benign MS (BMS), experiencing little disease progression and minimal disability, sometimes even decades after disease onset. But patients with BMS can only be diagnosed retrospectively, 10 or more years after MS onset. Although the general recommendation is that newly diagnosed MS patients immediately start treatment, it is not known whether BMS patients might also benefit from earlier treatment with disease modeling drugs (DMDs). Researchers analyzed more than 6,258 patients enrolled in The New York State MS Consortium (NYSMSC) to study the prevalence of BMS, the prognostic factors associated with BMS, and whether DMDs can maintain a benign status in people diagnosed with BMS at baseline. Because there is no consensus as to a definition of BMS, the researchers used three distinct but common criteria to identify this condition: 1. patients who had an Expanded Disability Status Scale (EDSS) equal to or lower than 2, and disease duration greater than 10 years; or, 2. patients with an EDSS of 3 or lower, and disease duration greater than 15 years; or, 3. patients with an EDSS of 3 or lower, but disease duration of 10 or more years. Depending on the classification criteria used, 19.8% to 33.3% of patients were characterized as having BMS at the time of enrollment. Findings showed that female sex and younger age at disease onset were positive prognostic factors of having BMS at baseline. Conversely, African-American race and progressive MS at onset were negative prognostic factors, meaning that a lower percentage of patients with those characteristics had a disease that followed a benign course. Among the 1,237 BMS patients identified with the most conservative criteria (No. 1), 742 were followed for a median of four years to examine the effect of DMD on BMS maintenance. The majority of patients who were on DMDs at enrollment or follow-up were receiving IFN-β1a (Avonex), IFN-β1b (Betaseron), or glatiramer acetate (Copaxone). One hundred and nine patients (14.7%) had no history of DMD use at enrollment and did not use DMD during the course of the study. Investigators found that both DMD use and longer disease duration significantly predicted the maintenance of BMS status at follow-up. This protective effect was particularly obvious in patients who were taking DMD both at baseline and follow-up. These findings suggest that early initiation and continued treatment with DMDs is beneficial for BMS patients, increasing their likelihood of maintaining a benign status. Print This Page About the Author Inês Martins, PhD Inês holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, Inês won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science. Tags AVONEX, BETASERON, Copaxone, disease duration, disease-modifying therapies (DMTs)
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8